| Unique ID issued by UMIN | UMIN000055011 |
|---|---|
| Receipt number | R000062846 |
| Scientific Title | Study to confirm the absorption enhancing effect of carotenoids by lactic acid bacteria and their metabolites |
| Date of disclosure of the study information | 2024/09/11 |
| Last modified on | 2025/09/05 10:17:24 |
Study to confirm the absorption enhancing effect of carotenoids by lactic acid bacteria and their metabolites
Study to confirm the absorption enhancing effect of carotenoids by lactic acid bacteria and their metabolites
Study to confirm the absorption enhancing effect of carotenoids by lactic acid bacteria and their metabolites
Study to confirm the absorption enhancing effect of carotenoids by lactic acid bacteria and their metabolites
| Japan |
Healthy subjects
| Adult |
Others
NO
To confirm whether carotenoid absorption is enhanced by the intake of lactic acid bacteria and their metabolites in human subjects.
Bio-availability
Plasma beta-carotene concentration
Plasma concentrations of other carotenoids and their metabolites.
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Prevention
| Food |
Subjects receive a single dose of carotenoids + the placebo foods. After the washout period (13 days or more), subjects receive a single dose of carotenoids + the active foods.
Subjects receive a single dose of carotenoids + the active foods. After the washout period (13 days or more), subjects receive a single dose of carotenoids + the placebo foods.
| 20 | years-old | <= |
| 35 | years-old | >= |
Male
1) Subjects giving written informed consent
2) Males aged 20 to 35 years old when consent acquisition
3) Subjects whose body mass index (BMI) is from 18.5 kg/m2 to 25.0 kg/m2
1) Subjects who routinely use pharmaceuticals, quasi-drugs, dietary supplement, and consume food for specified health uses, supplements containing carotenoids more than two days per week
2) Subjects who have chronic diseases necessitating treatments and/or medications
3) Subjects who have abnormal lipid metabolism, glucose metabolism, liver function, or kidney function
4) Subjects who received digestive surgical procedures
5) Habitual smokers
6) Subjects who participate in other clinical trials within the past month or have plans to participate in other clinical trials during this study period
7) Subjects who have food allergy
8) Subjects who is conscious of being prone to diarrhea from dairy products
9) Subjects who donate 200 mL of blood within a month, or 400 mL of blood within three month
10) Subjects who determine ineligible by the principal investigator or sub-investigator
40
| 1st name | Chiaki |
| Middle name | |
| Last name | Sanbongi |
Meiji Co., Ltd.
R&D Division
1920919
1-29-1 Nanakuni, Hachioji, Tokyo
042-632-5847
chiaki.sanbongi@meiji.com
| 1st name | Satomi |
| Middle name | |
| Last name | Ichikawa |
Meiji Co., Ltd.
R&D Division
1920919
1-29-1 Nanakuni, Hachioji, Tokyo
042-632-5847
satomi.ichikawa@meiji.com
Meiji Co., Ltd.
Meiji Co., Ltd.
Profit organization
Meiji Holdings Co., Ltd., CPCC Company Limited, Chiyoda Paramedical Care Clinic
Institutional Review Board of Chiyoda Paramedical Care Clinic
2F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo 103-0021, Japan
03-6225-9005
IRB@cpcc.co.jp
NO
| 2024 | Year | 09 | Month | 11 | Day |
Unpublished
40
Completed
| 2024 | Year | 07 | Month | 01 | Day |
| 2024 | Year | 06 | Month | 21 | Day |
| 2024 | Year | 08 | Month | 29 | Day |
| 2024 | Year | 09 | Month | 27 | Day |
| 2024 | Year | 07 | Month | 18 | Day |
| 2025 | Year | 09 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000062846